Market Closed -
Nasdaq
16:30:00 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
0.705
USD
|
-0.28%
|
|
+6.05%
|
-6.81%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21.84
|
57.69
|
296.3
|
176.8
|
108.7
|
127.3
|
-
|
-
|
Enterprise Value (EV)
1 |
21.84
|
57.69
|
296.3
|
176.8
|
108.7
|
127.3
|
127.3
|
127.3
|
P/E ratio
|
-
|
-
|
-8.83
x
|
-5.26
x
|
-3.11
x
|
-3.2
x
|
47
x
|
1.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1.52
x
|
0.64
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1.52
x
|
0.64
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-12,216,431
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
1.72
x
|
1.2
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,836
|
55,476
|
145,979
|
146,130
|
158,858
|
180,523
|
-
|
-
|
Reference price
2 |
0.7575
|
1.040
|
2.030
|
1.210
|
0.6844
|
0.7050
|
0.7050
|
0.7050
|
Announcement Date
|
19-12-16
|
20-12-16
|
21-12-15
|
22-12-22
|
23-12-29
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
83.59
|
200
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.6
|
-17.71
|
-23.53
|
-33.32
|
-36.73
|
-36.8
|
8.586
|
100.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
10.27%
|
50.34%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-23.05
|
-33.06
|
-31.97
|
-36.52
|
8.586
|
100.7
|
Net income
1 |
-
|
-
|
-24.51
|
-33.64
|
-33.69
|
-36.64
|
5.586
|
100.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
6.68%
|
50.34%
|
EPS
2 |
-
|
-
|
-0.2300
|
-0.2300
|
-0.2200
|
-0.2200
|
0.0150
|
0.5400
|
Free Cash Flow
|
-
|
-
|
-24.26
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-12-16
|
20-12-16
|
21-12-15
|
22-12-22
|
23-12-29
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
10.56
|
11.01
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.203
|
-9.259
|
-7.591
|
-8.917
|
-7.55
|
-
|
-10.69
|
-8.672
|
-10.12
|
-
|
-8.31
|
-8.532
|
-8.728
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.961
|
-9.225
|
-7.561
|
-8.864
|
-7.415
|
-
|
-10.38
|
-8.335
|
-9.8
|
-
|
-8.31
|
-8.532
|
-8.728
|
-
|
-
|
Net income
1 |
-4.961
|
-9.225
|
-7.561
|
-8.864
|
-7.991
|
-3.594
|
-10.53
|
-8.479
|
-11.1
|
-
|
-8.31
|
-8.532
|
-8.728
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0300
|
-0.0600
|
-0.0500
|
-0.0600
|
-0.0500
|
-0.0200
|
-0.0700
|
-0.0600
|
-0.0700
|
-0.0600
|
-0.0550
|
-0.0500
|
-0.0500
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-12-15
|
22-02-10
|
22-05-12
|
22-08-11
|
22-12-22
|
23-02-10
|
23-05-12
|
23-08-14
|
23-12-29
|
24-02-14
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-24.3
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
0.7000
|
0.5700
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.01
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-12-16
|
20-12-16
|
21-12-15
|
22-12-22
|
23-12-29
|
-
|
-
|
-
|
Last Close Price
0.705
USD Average target price
4
USD Spread / Average Target +467.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.81% | 127M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +28.07% | 12.14B | | +0.17% | 12.15B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|